Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes (Q37269261)

19 August 2017

Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes (English)

1 reference

triple-negative breast cancer

19 August 2017

1 reference

neoadjuvant chemotherapy

1 reference

1 reference

1 reference

6

Funda Meric-Bernstam

1 reference

19 August 2017

Jennifer A. Pietenpol

9

object named as

Jennifer A Pietenpol

1 reference

Ana Maria Gonzalez-Angulo

19 August 2017

0 references

5

object named as

Ana Maria Gonzalez-Angulo

1 reference

19 August 2017

10

Gabriel N Hortobagyi

1 reference

19 August 2017

Hiroko Masuda

1

1 reference

19 August 2017

Keith A Baggerly

2

1 reference

19 August 2017

Ying Wang

3

1 reference

19 August 2017

Ya Zhang

4

1 reference

19 August 2017

Vicente Valero

7

1 reference

19 August 2017

Brian D Lehmann

8

1 reference

19 August 2017

W Fraser Symmans

11

1 reference

19 August 2017

Naoto T Ueno

12

1 reference

19 August 2017

language of work or name

English

0 references

publication date

15 August 2013

1 reference

19 August 2017

Clinical Cancer Research

1 reference

19 August 2017

19

1 reference

19 August 2017

19

1 reference

19 August 2017

5533-5540

1 reference

Molecular characterization of basal-like and non-basal-like triple-negative breast cancer

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813597

TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813597

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813597

Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813597

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813597

Genomic index of sensitivity to endocrine therapy for breast cancer.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813597

Supervised risk predictor of breast cancer based on intrinsic subtypes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813597

Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813597

Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813597

Molecular classification of breast cancer: limitations and potential

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813597

The molecular portraits of breast tumors are conserved across microarray platforms

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813597

Repeated observation of breast tumor subtypes in independent gene expression data sets

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813597

Summaries of Affymetrix GeneChip probe level data

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813597

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813597

A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813597

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813597

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813597

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813597

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813597

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813597

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813597

Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813597

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system

3 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23948975

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/1078-0432.CCR-13-0799

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

23948975

1 reference